Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

4SC AG's CSO Outlines Epigenetics Strategy

Executive Summary

4SC AG Chief Science Officer says the German cancer drug developer is conducting a Phase II trial of lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma and is hoping for conditional EMA approval in 2019.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register